86 related articles for article (PubMed ID: 11749849)
1. DNA topoisomerase II as the primary cellular target for salvicine in Saccharomyces cerevisiae.
Meng LH; He XX; Zhang JS; Ding J
Acta Pharmacol Sin; 2001 Aug; 22(8):741-6. PubMed ID: 11749849
[TBL] [Abstract][Full Text] [Related]
2. Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation.
Meng LH; Ding J
Acta Pharmacol Sin; 2007 Sep; 28(9):1460-5. PubMed ID: 17723179
[TBL] [Abstract][Full Text] [Related]
3. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
[TBL] [Abstract][Full Text] [Related]
4. Salvicine triggers DNA double-strand breaks and apoptosis by GSH-depletion-driven H2O2 generation and topoisomerase II inhibition.
Cai YJ; Lu JJ; Zhu H; Xie H; Huang M; Lin LP; Zhang XW; Ding J
Free Radic Biol Med; 2008 Sep; 45(5):627-35. PubMed ID: 18582559
[TBL] [Abstract][Full Text] [Related]
5. Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes.
Meng LH; Zhang JS; Ding J
Biochem Pharmacol; 2001 Sep; 62(6):733-41. PubMed ID: 11551518
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
[TBL] [Abstract][Full Text] [Related]
7. Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase.
Lu HR; Zhu H; Huang M; Chen Y; Cai YJ; Miao ZH; Zhang JS; Ding J
Mol Pharmacol; 2005 Oct; 68(4):983-94. PubMed ID: 16024664
[TBL] [Abstract][Full Text] [Related]
8. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
Adjei AA; Charron M; Rowinsky EK; Svingen PA; Miller J; Reid JM; Sebolt-Leopold J; Ames MM; Kaufmann SH
Clin Cancer Res; 1998 Mar; 4(3):683-91. PubMed ID: 9533538
[TBL] [Abstract][Full Text] [Related]
9. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.
Nitiss JL; Liu YX; Harbury P; Jannatipour M; Wasserman R; Wang JC
Cancer Res; 1992 Aug; 52(16):4467-72. PubMed ID: 1322791
[TBL] [Abstract][Full Text] [Related]
10. The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.
Wang SJ; Peyrollier K; Bourguignon LY
Arch Otolaryngol Head Neck Surg; 2007 Mar; 133(3):281-8. PubMed ID: 17372087
[TBL] [Abstract][Full Text] [Related]
11. Effect of yerba mate (Ilex paraguariensis) tea on topoisomerase inhibition and oral carcinoma cell proliferation.
Gonzalez de Mejia E; Song YS; Ramirez-Mares MV; Kobayashi H
J Agric Food Chem; 2005 Mar; 53(6):1966-73. PubMed ID: 15769122
[TBL] [Abstract][Full Text] [Related]
12. DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells.
Lu HR; Meng LH; Huang M; Zhu H; Miao ZH; Ding J
Cancer Chemother Pharmacol; 2005 Mar; 55(3):286-94. PubMed ID: 15592835
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II is required for the G0-to-S phase transition in Drosophila Schneider cells, but not in yeast.
Hossain MS; Kurokawa K; Akimitsu N; Sekimizu K
Genes Cells; 2004 Oct; 9(10):905-17. PubMed ID: 15461662
[TBL] [Abstract][Full Text] [Related]
14. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II.
Kawiak A; Piosik J; Stasilojc G; Gwizdek-Wisniewska A; Marczak L; Stobiecki M; Bigda J; Lojkowska E
Toxicol Appl Pharmacol; 2007 Sep; 223(3):267-76. PubMed ID: 17618663
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II.
Hasinoff BB; Wu X; Begleiter A; Guziec LJ; Guziec F; Giorgianni A; Yang S; Jiang Y; Yalowich JC
Cancer Chemother Pharmacol; 2006 Jan; 57(2):221-33. PubMed ID: 16010589
[TBL] [Abstract][Full Text] [Related]
17. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II.
Li Y; Luan Y; Qi X; Li M; Gong L; Xue X; Wu X; Wu Y; Chen M; Xing G; Yao J; Ren J
Toxicol Sci; 2010 Dec; 118(2):435-43. PubMed ID: 20855424
[TBL] [Abstract][Full Text] [Related]
18. The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II.
Nitiss JL; Zhou J; Rose A; Hsiung Y; Gale KC; Osheroff N
Biochemistry; 1998 Mar; 37(9):3078-85. PubMed ID: 9485461
[TBL] [Abstract][Full Text] [Related]
19. Cells lacking DNA topoisomerase II beta are resistant to genistein.
López-Lazaro M; Willmore E; Austin CA
J Nat Prod; 2007 May; 70(5):763-7. PubMed ID: 17411092
[TBL] [Abstract][Full Text] [Related]
20. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]